Literature DB >> 21036224

Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses.

Katherine E Hanlon1, Todd W Vanderah.   

Abstract

The cannabinoid receptor type 1, found mainly on cells of the central and peripheral nervous system, is a major component of the endogenous cannabinoid system. Constitutive and endogenous activity at cannabinoid receptor type 1 regulates a diverse subset of biological processes including appetite, mood, motor function, learning and memory, and pain. The complexity of cannabinoid receptor type 1 activity is not limited to the constitutive activity of the receptor: promiscuity of ligands associated with and the capability of this receptor to instigate G protein sequestration also complicates the activity of cannabinoid receptor type 1. The therapeutic use of cannabinoid receptor type 1 agonists is still a heavily debated topic, making research on the mechanisms underlying the potential benefits and risks of cannabinoid use more vital than ever. Elucidation of these mechanisms and the quest for agonists and antagonists with greater specificity will allow a greater control of the side effects and risks involved in utilizing cannabinoids as therapeutic agents. In this chapter, we review a small subset of techniques used in the pharmacological application of and the behavioral effects of molecules acting at the paradoxical cannabinoid receptor type 1.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036224      PMCID: PMC5644031          DOI: 10.1016/B978-0-12-381298-8.00001-0

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  85 in total

1.  CB2 cannabinoid receptor-mediated peripheral antinociception.

Authors:  T P Malan; M M Ibrahim; H Deng; Q Liu; H P Mata; T Vanderah; F Porreca; A Makriyannis
Journal:  Pain       Date:  2001-09       Impact factor: 6.961

Review 2.  The endocannabinoid system: emotion, learning and addiction.

Authors:  Fabrício A Moreira; Beat Lutz
Journal:  Addict Biol       Date:  2008-04-16       Impact factor: 4.280

3.  Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.

Authors:  Giulio G Muccioli; Johan Wouters; Caroline Charlier; Gerhard K E Scriba; Teresa Pizza; Pierluigi Di Pace; Paolo De Martino; Wolfgang Poppitz; Jacques H Poupaert; Didier M Lambert
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

4.  Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor.

Authors:  A C Howlett; T M Champion; G H Wilken; R Mechoulam
Journal:  Neuropharmacology       Date:  1990-02       Impact factor: 5.250

5.  Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A.

Authors:  A N Gifford; C R Ashby
Journal:  J Pharmacol Exp Ther       Date:  1996-06       Impact factor: 4.030

6.  The role of mast cells in virus-induced inflammation in the murine central nervous system.

Authors:  F Mokhtarian; D E Griffin
Journal:  Cell Immunol       Date:  1984-07       Impact factor: 4.868

7.  Cannabinoids modulate hippocampal memory and plasticity.

Authors:  Hila Abush; Irit Akirav
Journal:  Hippocampus       Date:  2010-10       Impact factor: 3.899

8.  Voluntary exercise augments acute effects of CB1-receptor inverse agonist on body weight loss in obese and lean mice.

Authors:  Dan Zhou; Lauren P Shearman
Journal:  Pharmacol Biochem Behav       Date:  2004-01       Impact factor: 3.533

9.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  3 in total

Review 1.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

2.  Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation.

Authors:  András Iring; Éva Ruisanchez; Miriam Leszl-Ishiguro; Béla Horváth; Rita Benkő; Zsombor Lacza; Zoltán Járai; Péter Sándor; Vincenzo Di Marzo; Pál Pacher; Zoltán Benyó
Journal:  PLoS One       Date:  2013-01-04       Impact factor: 3.240

3.  Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018.

Authors:  David B Finlay; Thuy Nguyen; Thomas F Gamage; Shuli Chen; Daniel G Barrus; Purvi R Patel; Brian F Thomas; Jenny L Wiley; Yanan Zhang; Michelle Glass
Journal:  Pharmacol Res Perspect       Date:  2022-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.